Vaccination: an analysis of the health risks—part II

Townsend Letter for Doctors and Patients, Nov, 2003 by Gary Null, Martin Feldman

Also, a study published in the Journal of the American Medical Association in 1981 shows that 15 years after receiving rubella vaccination, one in 11 children lost protection from the vaccine and became susceptible to reinfection. (100) This is particularly worrisome because rubella infection is especially dangerous when contracted during pregnancy, since the fetus may develop malformations if exposed to the virus. Again, the lack of permanent immunity offered by vaccination is creating serious problems down the line.

Viera Scheibner has looked in depth into the research on rubella, and informs us: "As Cherry (1980) wrote, despite distribution of over 83 million doses of rubella vaccine since 1969, there were periodic upswings in incidence. There was also a shift in the age groups susceptible to rubella. "'Essentially, we have controlled the disease in persons 14 years of age or younger but have given it a free hand in those 15 or older." (101,102)

Scheibner adds: "In August 1991, the Institute of Medicine released a report on adverse effects of pertussis and rubella vaccines. The evidence indicated a causal relationship between RA 27/3 rubella vaccine and acute arthritis in 13% to 15% of adult women. Also some individuals were shown to go on to develop chronic arthritis." (103)

Further Readings: Articles associate the MMR vaccine with adverse reactions affecting the nervous system, (104-108) the GI tract, (109) and joints. (110-112)

In Part 3: The smallpox and rotavirus vaccines, provocation diseases associated with vaccines, economic, political and legal issues, and the right to refuse vaccination.

References

1. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000 May 19; 49(RR-5):1-22.

2. Ibid.

3. Ibid.

4. Kinnunen E, et al. Nationwide oral poliovirus vaccination campaign and the incidence of Guillain-Barre Syndrome. Am J Epidemiol 1998 Jan 1; 147(1):69-73.

5. Uhari M, et al. Cluster of childhood Guillain-Barre cases after an oral poliovaccine campaign. Lancet 1989 Aug 19; 2(8660):440-1.

6. Friedrich F, et al. Temporal association between the isolation of Sabin-related poliovirus vaccine strains and the Guillain-Barre syndrome. Rev Inst Med Trop Sao Paulo 1996 Jan-Feb; 38(1):55-8.

7. Friedrich F. Rare adverse events associated with oral poliovirus vaccine in Brazil. Braz J Med Biol Res 1997 Jun; 30(6):695-703.

8. Ibid.

9. Fisher SG, et al. Cancer risk associated with simian virus 40 contaminated polio vaccine. Anticancer Res 1999 May-Jun; 19(3B):2173-80.

10. Martini F, et al. Simian-virus-40 footprints in human lymphoproliferative disorders of HIV- and HIV patients. Int J Cancer 1998 Dec 9; 78(6):669-74.

11. Ibid.

12. Martini F, et al. Simian virus 40 footprints in normal human tissues, brain and bone tumours of different histotypes. Dev Biol Stand 1998; 94:55-66.

13. Martini F, et al. SV40 early region and large T antigen in human brain tumors, peripheral blood cells, and sperm fluids from healthy individuals. Cancer Res 1996 Oct 15; 56(20):4820-5.